Evonik
Tuesday, October 10, 2023
12:30 p.m. EDT

From micro to nano - PLA-PEG block copolymers enable nanoparticle drug products for the treatment of new therapeutic modalities

Back to overview

Overview

Nanomedicine encompasses a wide variety of formulations including polymeric nanoparticles, liposomes, lipid nanoparticles, micelles, polymersomes, nano-emulsions, nanotubes, and nanofibers. These nano-sized constructs can be used to overcome drug delivery challenges such as drug solubilization, API targeting, protection of sensitive APIs from degradation and/or immune responses, and API transport across biological barriers. This webinar will focus on biodegradable polymeric nanoparticle formulations and the products and processes required for achieving sub-micron particle sizes.

Many traditional microparticle applications rely on copolymers of lactide and glycolide (LG polymers) for controlled and/or sustained release. Nanoparticles of LG polymers, while also potentially imparting some level of controlled drug release, are intended to effect targeted delivery of an API to a desired location rather than sustained systemic delivery. The amount of applied energy required to generate particles in the nanometer range can be reduced by incorporating a poly(ethyleneglycol) (PEG) block into the LG polymer chain. While traditional LG polymers can be used, the amphiphilicity imparted by PLA-PEG di-block copolymers, makes them especially suited for nanoparticle formation. By adjusting the relative molecular weight of the mPEG and poly(DL-lactide) blocks, the excipient properties and formulation properties can be carefully tuned.

While excipient quality and security of supply is paramount, the process by which nanoparticles are made is also critical to the end drug product. Current processes include high-pressure homogenization, high-shear mixing, probe sonication, and microfluidics, among others, which often result in temperature and pressure elevations that are detrimental to sensitive APIs and high-shear forces that can cause nanoparticle deformation and aggregation. The process scale limitations also inherent to these batch processes severely limit their applicability to commercial-scale and peptide/protein-based nanoparticle formulations. As a result, regulatory agencies continue to push for continuous nanoparticle processes with robust scale-up potential.

Learning Objectives

  • The current limitations of nanoparticle manufacturing and how to overcome them
  • The benefits of PLA-PEG block copolymers for nanoparticle formation

Experts featuring this session

Dr. Whitney Beysselance Moro
Director Strategic & Technical Marketing
Evonik Health Care

Vita
Whitney Moro joined Evonik as part of the acquisition of the LACTEL® Absorbable Polymers line in 2021. She is currently the Director of Strategic and Technical Marketing for Evonik’s Parenteral Drug Delivery Solutions business.

Prior to the acquisition, Whitney served as the Director of Scientific and Technical Operations for the Lactel group within DURECT Corporation. In this capacity, she was responsible for managing the analytical testing and development for all LACTEL® products, developing and optimizing manufacturing and purification processes for new products (including glucose star polymer), and bridging the gap between technical and customer support for new and existing clients.

Whitney obtained her PhD in organic medicinal chemistry from the University of Alabama in Birmingham (UAB), USA, which was followed by postdoctoral training at UAB in the discovery of small-molecule antibacterial drugs with activity against novel therapeutic targets for the treatment of biowarfare agents.

Register now

Details

Webinar language
English

Venue

Online

Questions?

Julia Born
Market Communications Health Care
+49 6151 18 4984 E-Mail
Register now
Evonik Health Care
Company Information
Legal Notice
Privacy Policy